# Atacicept in Multiple Glomerular Diseases

> **NCT06983028** · PHASE2 · RECRUITING · sponsor: **Vera Therapeutics, Inc.** · enrollment: 200 (estimated)

## Conditions studied

- pMN
- IgAN
- Nephrotic Syndrome
- MCD
- FSGS

## Interventions

- **DRUG:** Atacicept

## Key facts

- **NCT ID:** NCT06983028
- **Lead sponsor:** Vera Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-07
- **Primary completion:** 2027-11
- **Final completion:** 2027-11
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06983028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06983028, "Atacicept in Multiple Glomerular Diseases". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06983028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*